Quarterly report · Q2
4671.TEDINET S100PKQ2
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥24.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥50.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥24.7bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥1.7bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥3.1bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥1.9bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥5.8bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.3bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.9bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.3bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.1bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥2.1bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥38.7bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥40.3bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥39.1bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥14.4bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥16.8bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥24.3bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥23.5bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥22.4bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥10.9bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥10.6bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥10.9bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.6bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥12.1bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.6bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥4.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.0bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥249m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥503m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥937m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥2.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.0bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥107.5 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥65.16 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥339 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥204.38 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥122.9 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥107.18 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥336.99 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥203.77 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 62.6% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.1% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.1% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥4m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥4m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥213m |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥16.2bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥16.2bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥4m |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.6bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥320m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥24.2bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥24.2bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥4m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥8m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥8m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥177m |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥16.6bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥16.6bn |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥7m |
| jpcrp040300-q2r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥2.8bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥8.1bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥8.1bn |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥0 |
| jpcrp040300-q2r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥523m |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥24.7bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥24.7bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥8m |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥3.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 519
| Item | Context | Value | Unit |
|---|---|---|---|
| Other ca | Prior1YearInstant | 2304000000 | JPY |
| Other ca | CurrentQuarterInstant | 1694000000 | JPY |
| Allowance for doubtful accounts ca | Prior1YearInstant | -1000000 | JPY |
| Allowance for doubtful accounts ca | CurrentQuarterInstant | -1000000 | JPY |
| Current assets | Prior1YearInstant | 22668000000 | JPY |
| Current assets | CurrentQuarterInstant | 21425000000 | JPY |
| Buildings and structures | Prior1YearInstant | 8586000000 | JPY |
| Buildings and structures | CurrentQuarterInstant | 8651000000 | JPY |
| Accumulated depreciation buildings and structures | Prior1YearInstant | -4471000000 | JPY |
| Accumulated depreciation buildings and structures | CurrentQuarterInstant | -4612000000 | JPY |
| Buildings and structures net | Prior1YearInstant | 4114000000 | JPY |
| Buildings and structures net | CurrentQuarterInstant | 4038000000 | JPY |
| Land | Prior1YearInstant | 4589000000 | JPY |
| Land | CurrentQuarterInstant | 4594000000 | JPY |
| Lease assets ppe | Prior1YearInstant | 1328000000 | JPY |
| Lease assets ppe | CurrentQuarterInstant | 1286000000 | JPY |
| Accumulated depreciation lease assets ppe | Prior1YearInstant | -721000000 | JPY |
| Accumulated depreciation lease assets ppe | CurrentQuarterInstant | -792000000 | JPY |
| Lease assets net ppe | Prior1YearInstant | 607000000 | JPY |
| Lease assets net ppe | CurrentQuarterInstant | 493000000 | JPY |
| Other ppe | Prior1YearInstant | 5034000000 | JPY |
| Other ppe | CurrentQuarterInstant | 5085000000 | JPY |
| Accumulated depreciation other ppe | Prior1YearInstant | -3687000000 | JPY |
| Accumulated depreciation other ppe | CurrentQuarterInstant | -3704000000 | JPY |
| Other net ppe | Prior1YearInstant | 1346000000 | JPY |
| Other net ppe | CurrentQuarterInstant | 1381000000 | JPY |
| Property plant and equipment | Prior1YearInstant | 10658000000 | JPY |
| Property plant and equipment | CurrentQuarterInstant | 10508000000 | JPY |
| Goodwill | Prior1YearInstant | 28000000 | JPY |
| Goodwill | CurrentQuarterInstant | 20000000 | JPY |
| Other ia | Prior1YearInstant | 466000000 | JPY |
| Other ia | CurrentQuarterInstant | 404000000 | JPY |
| Intangible assets | Prior1YearInstant | 495000000 | JPY |
| Intangible assets | CurrentQuarterInstant | 424000000 | JPY |
| Investment securities | Prior1YearInstant | 3801000000 | JPY |
| Investment securities | CurrentQuarterInstant | 3761000000 | JPY |
| Other ioa | Prior1YearInstant | 2641000000 | JPY |
| Other ioa | CurrentQuarterInstant | 2569000000 | JPY |
| Allowance for doubtful accounts ioa by group | Prior1YearInstant | -8000000 | JPY |
| Allowance for doubtful accounts ioa by group | CurrentQuarterInstant | -8000000 | JPY |
| Investments and other assets | Prior1YearInstant | 6434000000 | JPY |
| Investments and other assets | CurrentQuarterInstant | 6321000000 | JPY |
| Noncurrent assets | Prior1YearInstant | 17588000000 | JPY |
| Noncurrent assets | CurrentQuarterInstant | 17254000000 | JPY |
| Assets | Prior1YearInstant | 40256000000 | JPY |
| Assets | CurrentQuarterInstant | 38680000000 | JPY |
| Notes and accounts payable trade | Prior1YearInstant | 5384000000 | JPY |
| Notes and accounts payable trade | CurrentQuarterInstant | 4980000000 | JPY |
| Short term loans payable | Prior1YearInstant | 300000000 | JPY |
| Short term loans payable | CurrentQuarterInstant | 200000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |